BRIEF-Zai Lab Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy

Reuters
Apr 01
BRIEF-<a href="https://laohu8.com/S/ZAILF">Zai Lab</a> Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy

Zai Lab Ltd 9688.HK:

  • ZAI LAB ANNOUNCES GLOBAL CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE NOVEL DLL3 ADC, ZOCILURTATUG PELITECAN, IN COMBINATION WITH A BISPECIFIC T-CELL ENGAGER THERAPY

  • ZAI LAB LTD - ANNOUNCES GLOBAL CLINICAL TRIAL COLLABORATION WITH AMGEN FOR ES-SCLC

Source text: ID:nBw28MYRka

Further company coverage: 9688.HK

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10